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Abstract 
Dexamethasone has been found to reduce the incidence of high altitude pulmonary edema. 
Mechanisms explaining this effect still remain unclear. We assessed the effect of 
dexamethasone using established cell lines including rat alveolar epithelial cells (AEC), 
pulmonary artery endothelial cells (RPAEC) and alveolar macrophages (MAC) in an 
environment of low oxygen, simulating a condition of alveolar hypoxia as found at high 
altitude. Inflammatory mediators and ion transporter expression were quantified. Based on 
earlier results we hypothesized that hypoxic conditions trigger inflammation. 
AEC, RPAEC and MAC, preincubated for 1 hour with or without dexamethasone (10-7 mol/l), 
were subsequently exposed to mild hypoxia (5% O2, or normoxia as control) for 24 hours. 
mRNA and protein levels of cytokine-induced neutrophil chemoattractant-1, monocyte 
chemotactic protein-1 and interleukin-6 were analyzed. mRNA expression and functional 
activity of the apical epithelial sodium channel and basolateral Na+/K+-ATPase were 
determined using radioactive marker ions. 
In all three types of pulmonary cells hypoxic conditions lead to an attenuated secretion of 
inflammatory mediators, which was even more pronounced in dexamethasone pretreated 
samples. Function of Na+/K+-ATPase was not significantly influenced by hypoxia or 
dexamethasone, while activity of epithelial sodium channel was decreased under hypoxic 
conditions. When preincubated with dexamethasone, however, transporter activity was 
partially maintained.  
These findings illustrate that long term hypoxia does not trigger an inflammatory response. 
The ion transport across apical epithelial sodium channels under hypoxic conditions is 
ameliorated in cells treated with dexamethasone. 
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Introduction 
Alveolar hypoxia has been shown to induce injury within the lung parenchyma including 
epithelial lung damage, capillary leakage and edema formation [1]. Conditions potentially 
imparting states of alveolar hypoxia include exposure to high altitudes, lung diseases, bulbar 
cerebral injuries, and overdoses of narcotic agents (alcohols, barbiturates, opioids). 
In particular, high altitude pulmonary edema (HAPE) is a high permeability pulmonary edema 
caused by increased pulmonary capillary pressure leading to a protein rich edema fluid [2]. 
Elevated pulmonary capillary pressure is most likely induced by hypoxic pulmonary 
vasoconstriction. Pulmonary vasodilators are efficient in treating and preventing HAPE, 
suggesting that elevated pulmonary artery pressure is indeed a crucial pathophysiologic 
mechanism [3, 4]. Administration of corticosteroids such as dexamethasone has been found to 
reduce the incidence of HAPE [5, 6]. Mechanisms explaining this effect are still not 
thoroughly clear: Besides a decrease of the systolic pulmonary artery pressure, an 
amelioration of hypoxia-induced impairment of fluid clearance has been suggested as 
underlying mechanism of the dexamethasone effect [6].  Moreover, there is a known crosslink 
between hypoxia and inflammation pathways [7]. Proinflammatory proteins such as 
interleukin-6 (IL-6) and C-reactive protein (CRP) have been found to be increased in response 
to high altitude exposure [8]. Attenuation in proinflammatory cytokine expression by 
corticosteroids might therefore also be an underlying factor for the preventing effect of 
dexamethasone. 
In inflammatory processes, chemokines such as cytokine-induce neutrophil chemoattractant 
protein-1 CINC-1) [9], monocyte chemotactic protein-1 (MCP-1) [10] and IL-6 [11] are 
among the most important inflammatory mediators directly or indirectly orchestrating the 
effector cell migration to the location of tissue injury, where an elevated expression of 
adhesion molecules including intercellular adhesion molecules (ICAM-1) mediate effector-
target cell interaction in the respiratory and vascular compartment of the lung [12, 13] (Figure 
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1), an interplay between alveolar epithelial (AEC), endothelial cells (RPAEC) and alveolar 
macrophages (MAC). 
In this study, we hypothesized that dexamethasone treatment before and during exposure to 
hypoxic conditions attenuates inflammatory mediator synthesis in AEC, RPAEC and MAC in 
vitro and enhances alveolar water clearance in AEC. The study aims at a better understanding 
of the effect of dexamethasone on alveolar water clearance and the secretion of 
proinflammatory mediators under long-term hypoxic conditions as found in high altitudes. 
Insights regarding the effect of dexamethasone in alveolar hypoxia may have implications on 
the future treatment of HAPE. 
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Material & Methods  
Experimental design 
Conditions at high altitude were simulated exposing AEC, RPAEC as well as MAC to 5% 
hypoxia during 24h. After preincubation with either dexamethasone or NaCl containing cell 
culture medium for 1 hour, cells were exposed for 24 hours to hypoxia or normoxia in a cell 
incubator (Bioblock, Ittigen, Switzerland) with adjustable O2 levels. Oxygen concentration 
was reached by flushing nitrogen through the exposure chamber and continuously monitored 
by an oxygen sensor. During hypoxic conditions, oxygen and carbon dioxide concentrations 
were both 5%, whereas under normoxic control conditions, oxygen was 21% and CO2 was 
5%. Temperature was kept constant at 37°C during all experiments. After 24 hour-exposure to 
the respective atmosphere, supernatants and or cells were immediately collected without 
reoxygenation. 
 
Alveolar epithelial cells (L2)  
The L2 cell line (CCL 149; American Type Culture Collection, Rockville, MD, USA) was 
used as representatives of rat alveolar epithelial cells [14]. They were cultured in Dulbecco’s 
modified eagle medium (DMEM; Invitrogen AG, Basel, Switzerland), enriched with 10% 
fetal bovine serum (FBS) and 1% penicillin–streptomycin. The cells were grown in uncoated 
35x10 mm plates (Corning Inc., Corning, NY, USA) to a confluent monolayer. Before 
performing the experiments, the medium was changed to DMEM/1% FBS. 
 
Rat pulmonary artery endothelial cells (RPAEC) 
Rat pulmonary artery endothelial cells, kindly provided by Dr. Roscoe Warner, (Department 
of Pathology, University of Michigan, Ann Arbor, MI, USA), were cultured in Dulbecco’s 
modified eagle medium (DMEM) with 10% FBS, 1% penicillin–streptomycin and 1% 
HEPES. Prior to the experiments, medium was changed to DMEM/1% FBS. 
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Rat alveolar macrophages (MAC) 
The rat alveolar macrophage cell line CRL-2192 was obtained from the American Type 
Culture Collection (Manassas, VA, USA). Alveolar macrophages were cultured in nutrient 
mixture F-12Ham (Ham’s F-12; Invitrogen Corporation, Carlsbad, CA, USA), completed 
with 15% FBS, 5% penicillin/streptomycin (10 000 U/l) (Invitrogen Corporation) and 5% 
HEPES (Invitrogen Corporation). The cells were grown to confluence. At day 3 cells were 
centrifuged for 3 min at 1250 rpm, and experiments were performed. 
All three types of cells are represented by well established pulmonary cell lines. 
 
Dexamethasone treatment 
Dexamethasone (Mephamesone-4®, Mepha Pharma AG, Aesch, Switzerland) was dissolved 
in NaCl and diluted in culture medium DMEM/1%FBS to a concentration of 10-7 mol/l. In 
order to investigate the effect of dexamethasone on the secretion of inflammatory mediators 
and ion channel function under normoxic and hypoxic conditions, cells were pre-incubated 
(Bioblock, Ittigen, Switzerland) with dexamethasone-containing medium 1 hour before 
exposure to hypoxia/normoxia for 24 hours (NaCl served as negative control). Cells therefore 
underwent in total 25 hours of exposure to dexamethasone before measurements. 
 
Cytotoxicity and viability tests 
To determine possible cytotoxicity mediated by dexamethasone and/or hypoxia, we measured 
lactate dehydrogenase concentrations (LDH) (Promega, Madison, WI, USA) in cell 
supernatants. The cell’s viability was monitoring by performing 3-(4, 5-dimethylthiazolyl-2)-
2, 5-diphenyltetrazolium bromide (MTT) assays [15]. 
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Enzyme linked immunoabsorbent assay (ELISA) 
Sandwich ELISAs were performed according to the manufacturer’s protocols. The 
concentration of the chemokines CINC-1 (R&D Systems Europe Ltd, Abingdon, UK), MCP-
1 (BD Biosciences, San Diego, CA, USA), and the cytokine interleukin-6 (IL-6; R&D 
Systems Europe Ltd, Abingdon, UK) were measured. Endothelial cells did not express any 
IL-6 protein. Cell-based ICAM-1 ELISA was performed on AEC and RPAEC as previously 
described [16].  
 
RNA-extraction, reverse transcriptase and real-time PCR 
After collection of the supernatants, cell lysate was harvested using lysing buffer provided in 
the RNeasy® Mini Kit (Qiagen, Basel, Switzerland). RNA was isolated according to the 
manufacturer’s protocol. After determination of RNA amount (NanoDrop ND 1000, 
NanoDrop Technologies, Delaware, USA), reverse transcription from RNA to cDNA was 
performed (GeneAmp 9700 system, Applied Biosystems, Branchburg, NJ, USA). The 
TaqMan Real-Time PCR System 7500 Fast (Applied Biosystems, Branchburg, NJ, USA) was 
used to amplify and simultaneously quantify the targeted molecules. Following primers were 
designed: CINC-1, MCP-1, IL-6, ICAM-1, α-ENaC and α-Na+/K+-ATPase [17]. Samples 
were normalized to the housekeeping gene 18S (all primers from Microsynth, Balgach, 
Switzerland; labelled TaqMan probes from Roche Applied Science, Switzerland; for details 
see supporting information Table S8).  
 
Stimulation of AEC with dimethyloxallyl glycine (DMOG) instead of hypoxia 
After preincubation with either dexamethasone or NaCl for 1 hour, AEC were incubated over 
a time period of 24 hours with DMOG (Sigma-Aldrich, Hamburg, Germany) at a 
concentration of 1mM [18] instead of hypoxia (5%). 
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22Na influx studies 
Sodium influx through ENaC was measured with the method established by Clerici et al [19]. 
Cells were rinsed twice and preincubated at 37°C for 20 min in buffered sodium-free medium. 
Thereafter cells were incubated with 22Na for six minutes, and uptake was stopped by washing 
the cell monolayer. Events were detected by a liquid scintillation counter (Tri-carb 2900TR, 
Packard, IL, USA). To estimate the portion of ENaC in total ion flux 22Na uptake inhibited by 
amiloride (100 µM; Sigma-Aldrich, Hamburg, Germany) was also measured.  
 
86Rubidium influx Studies 
86Rubidium (86Rb), serving as surrogate for potassium [20], was used to quantify ion transport 
via Na+/K+-ATPase. Radioactive counts were measured using Tri-carb 2900TR, Packard, IL, 
USA. The portion of 86Na uptake inhibited by Ouabain was also measured reflecting the 
portion of Na+/K+-ATPase in total 86Na flux (4 mM; Sigma-Aldrich, Hamburg, Germany). 
 
Statistics 
Data are summarized as medians (quartiles). Matlab Software (MATLAB 2008R; 
Mathworks) and SPSS (SPSS Inc, Chicago, Ill) was used to perform all statistical analysis. 
Linear regression analysis was performed to assess the influences of hypoxia, dexamethasone 
and changes in viability / MTT (independent variables) on inflammatory mediator levels 
(dependent variable) (see Table S2-S5 for the detailed statistic tables in the supporting 
information). Spearmans rank correlation analysis was performed to compare inflammatory 
mediator protein concentration to their related mRNA levels. Influence of hypoxia, 
dexamethasone treatment or viability / MTT (independent variables) on ion fluxes (dependent 
variable) was also analyzed using linear regression (see Table S6-S7 for the detailed statistic 
tables in the supporting information). All experiments were at least performed three times 
each with four independent samples per group.  
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Results 
Inflammatory response in AEC upon exposure hypoxic conditions 
After 24 hours of exposure to hypoxic conditions both CINC-1 (-39%, p<0.001, R2: 0.568) 
and MCP-1 (-42%, p < 0.001, R2: 0.757) protein expressions were decreased (Figure 2). This 
was not observed for IL-6 protein or ICAM-1 expression levels (supporting information, 
Figure S1), which remained unchanged. Dexamethasone incubation prior to hypoxia was 
found to decrease CINC-1 (-56%, p < 0.001, R2: 0.568) and MCP-1 (-82%, p < 0.001, R2: 
0.787) protein levels even more compared to mere hypoxia treatment. Exposure to 
dexamethasone alone under normoxic conditions decreased CINC-1 (-32%, p < 0.001, R2: 
0.568), MCP-1 (-82%, p < 0.001, R2: 0.757), and IL-6 protein expression (-36%, p = 0.004, 
R2: 0.380). No changes in ICAM-1 protein levels were observed. Measured mRNA 
expression of CINC-1, MCP-1, and IL-6 (Figure 2) was in good correlation with observed 
inflammatory mediator protein levels (supporting information, Table S1), except for 
ICAM-1 where a decrease upon exposure to hypoxic conditions and dexamethasone was 
found on mRNA (-33%, p = 0.010, R2: 0.126), but not on protein level.  
 
lnflammatory mediator expression in RPAEC after exposure to hypoxia 
Inflammatory response upon hypoxic conditions and influence of dexamethasone was also 
evaluated in RPAEC mimicking the response of endothelial cells from the vascular 
compartment in vitro (Figure 3). In contrast to results from AEC, only a decrease in CINC-1 
protein levels after 24 hours exposure to hypoxia was found (-35%, p < 0.001, R2: 0.772). No 
significant changes were measured regarding mRNA levels of all cytokines, and protein 
expression of MCP-1 and ICAM-1. IL-6 protein was not detectable in supernatants of 
RPAEC. Similar to results from AEC, addition of dexamethasone attenuated MCP-1 protein 
and mRNA expression under normoxic (-47%, p < 0.001, R2: 0.575) and hypoxic conditions 
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(-52%, p < 0.001, R2: 0.575). ICAM-1 mRNA (- 44%, p = 0.002, R2: 0.317), but not protein 
levels were slightly decreased after exposure to dexamethasone alone under normoxic 
conditions (Figure 3).  
 
Inflammatory mediator expression in MAC after exposure to hypoxia 
Effector cells response upon long-term incubation for 24 hours under hypoxic conditions of 
5% oxygen was studied in alveolar macrophages. An attenuated expression of MCP-1 protein 
(-32%, p < 0.001, R2: 0.851) and mRNA (-33%, p = 0.031, R2: 0.524) was found after 
exposure to hypoxia (Figure 4). Addition of dexamethasone also provoked an even more 
pronounced decrease in MCP-1 protein levels (-91%, p < 0.001, R2: 0.851). CINC-1 and IL-6 
protein concentrations were below detection levels. Hypoxia attenuated ICAM-1 mRNA 
expression (-65%, p<0.001, R2: 0.919). Dexamethasone incubation prior to hypoxia was 
found to decrease ICAM-1 (-80%, p < 0.001, R2: 0.919) protein levels even more compared to 
mere hypoxia treatment. 
 
Activation of hypoxic-inducible factor attenuates inflammatory mediator 
expression 
Additional experiments in AEC were performed using DMOG to investigate whether 
activation of hypoxia-inducible factor-1α (HIF-1α) attenuates inflammatory mediator 
expression comparable to exposure to hypoxia (5% O2). An attenuation of CINC-1 protein 
expression of -44% was measured after incubation with DMOG (p < 0.001, R2: 0.934) 
(Figure 5). In the DMOG and dexamethasone group CINC-1 protein expression was even 
more decreased (-59%, p < 0.001, R2: 0.934). Stimulation with DMOG also attenuated MCP-
1 protein secretion by -89% compared to control (p < 0.001; R2: 0.863). Incubation of both 
dexamethasone and DMOG decreased MCP-1 protein by -80% (p < 0.001; R2: 0.863). No 
differences were observed between samples incubated with DMOG and DMOG in the 
presence of dexamethasone. 
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Influence of hypoxia and dexamethasone on ion transporter expression and 
activity 
To assess the influence of dexamethasone on sodium transport, mRNA expression of the 
basolateral sodium/potassium ATPase and of the apical epithelial sodium channels were 
measured (Figure 1). In addition, the influence of hypoxia and dexamethasone on inhibitor-
sensitive (reflecting ENaC and Na+/K+-ATPase function) and inhibitor-insensitive portion of 
the total sodium transport was determined in 22Na and 86Rb influx studies. Total 22Na flux was 
significantly decreased upon hypoxic conditions (-42%, p < 0.001, R2: 0.415). When cells 
were preincubated with dexamethasone before exposure to hypoxic conditions, however, Na+ 
influx was partially maintained (-30% compared to control; p = 0.001; R2: 0.415). Amiloride 
inhibited on average 45% of total 22Na flux (-45%, p < 0.001, R2: 0.415) which in turn reflects 
the portion of ENaC in total 22Na flux. Amiloride-insensitive 22Na flux was not significantly 
influenced by dexamethasone or hypoxia. 
Preincubation with dexamethasone slightly increased mRNA expression of Na+/K+-ATPase 
in comparison to normoxic control after 24 hours (+36%,  p = 0.021, R2: 0.268). In 
experiments using 86Rb as marker of ion flux, no increased Na+/K+-ATPase activity upon 
dexamethasone treatment was observed which is in contrast to results from mRNA assays. 
Addition of dexamethasone under normoxic condition even marginally decreased total 86Rb 
flux (-14%, p < 0.001, R2: 0.900). Ouabain impaired 86Rubidium uptake on average by -68% 
(p < 0.001, R2: 0.900) reflecting the portion of Na+/K+-ATPase in total 86Rb flux. However, 
oubain-insensitive 86Rubidium uptake was decreased by -10% in the presence of 
dexamethasone and hypoxia (-11%, p = 0.017, R2: 0.582). 
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Assessment of viability after exposure to hypoxic conditions and 
dexamethasone 
Viability of the cells after exposure to hypoxic conditions and dexamethasone treatment was 
monitored by performing MTT assays (Figure 7). No relation between changes in MTT and 
inflammatory mediator expression was found for AEC, RPAEC or MAC. 86Rb and 22Na 
influx studies were not influenced by changes in MTT. 
 
Discussion 
With regard to the formation of hypoxia-induced pulmonary edema, the role of inflammation 
has been subject of numerous investigations, however, studies under isolated conditions (i.e. 
accurately controlled oxygen concentration, timing, and extent of reoxygenation) remain rare 
[8, 12, 21, 22]. In this study, we evaluated the inflammatory response in pulmonary epithelial 
and endothelial cells as well as in alveolar macrophages after 24 hours of hypoxia (5% 
oxygen; simulating conditions at high altitudes). Hypoxia induced a downregulation of 
inflammatory mediators, which was even more accentuated in the presence of dexamethasone. 
As marker of water flux, the activity of sodium transport in alveolar epithelial cells was 
determined. Under hypoxia, sodium ion transport was impaired in AEC, but transport activity 
of ENaC could be maintained when cells were pre-incubated with dexamethasone. 
The influence of hypoxia on inflammation is discussed controversially in the literature: in 
previous studies, hypoxia has been shown to promote inflammation by activation of the 
inflammatory transcription factor NF-κβ, by prolonging neutrophil survival [23], and by 
induction of Toll-like receptors [24]. Raised levels of MCP-1 protein in macrophages were 
described in recent work of Chao and Madjdpour after exposure to conditions of low oxygen 
[25, 26]. Chao et al. demonstrated that alveolar macrophage-derived MCP-1 plays a crucial 
role in initiation of systemic inflammation under hypoxic conditions, where exposure of 
primary culture of rat alveolar macrophages to various oxygen concentrations (0%, 5%, 10%, 
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and 15%) induced a nearly 20-fold increase of MCP-1 expression. These macrophages, 
however, were exposed to hypoxia for only 30 min. In the present in vitro data we show that 
after an exposure of 24 hours mild hypoxia does not necessarily induce inflammation in 
pulmonary cells. In our study, an even attenuating effect of hypoxia was found for all three 
types of pulmonary cells. This was underlined by additional experiments using DMOG, in 
which also a downregulation of MCP-1 and CINC-1 protein expression has been found 
comparable to the experiments with hypoxia (5% oxygen). All these observations suggest that 
HIF-1α might mediate anti-inflammatory effects, which would be in good accordance with 
findings from previous studies [27-29]. However, from our data we cannot exclude that 
hypoxia may trigger inflammation at a very early phase [26]. Also further in vitro and in vivo 
studies under controlled conditions are required to ultimately clarify the role, mechanisms and 
dynamics of inflammation in hypoxia in general and the pathogenesis of hypoxia-induced 
edema. 
Epithelial sodium channels have been identified as the major pathway for apical sodium entry 
in AEC thereby controlling fluid clearance from the alveolar space. In close interplay with 
apical sodium channels, basolateral Na+/K+-ATPase is a key player involved in 
transepithelial sodium transport by alveolar cells, and ensures efficient vectorial sodium 
transport [30, 31]. In the present study, 5% oxygen did not significantly influence mRNA 
expression of Na+/K+-ATPase and ENaC. Comparisons with other studies are delicate as 
exposure time, concentration of oxygen and cell types are different [32-34]. Because injury-
induced changes in the mRNA expression of sodium transporters might not necessarily be in 
correlation with an impaired function, sodium transport in our experimental setting was 
additionally determined using radioactive marker ions. Sodium transport was significantly 
decreased in the presence of hypoxia, and was maintained when cells were pretreated with 
dexamethasone prior to hypoxic conditions. A similar observation was made in the work of 
Güney et al. [34]: In freshly prepared AEC of type II character the authors did not find a 
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difference in mRNA expression of ENaC in hypoxia or with dexamethasone exposure, while 
the impaired capacity of the epithelial sodium channel was positively influenced by 
dexamethasone [34]. A study from Mairbäurl et al. described an inhibition of the amiloride-
sensitive portion of the active sodium transport to 55% upon exposure to 5% oxygen in 
primary cultured adult rat alveolar epithelial cell monolayers [35]. In our study mRNA 
expression of Na+/K+-ATPase was upregulated by dexamethasone. Activity, however, 
remained unchanged upon exposure to hypoxia and/or dexamethasone. Several factors might 
account for the differences in findings among different studies, whereas the concentration of 
oxygen (5% vs. 1.5%), exposure time (24 hours vs. 48 hours) and extent of reoxygenation 
might be of utmost importance. 
Although numerous studies have investigated different aspects of hypoxia and high altitude 
pulmonary edema, it remains as hitherto controversial whether the inflammatory response 
upon alveolar hypoxia is just a secondary event to an edema of hydrostatic genesis (hypoxic 
pulmonary vasoconstriction; impaired fluid clearance due to decreased sodium and water 
transport [6]) or one of the causative factors in alveolar edema formation (such as in acute 
respiratory distress syndrome) [36]. The present study was performed with a special focus on 
in vitro evaluation of changes possibly observed in HAPE the findings might also play an 
important role in acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS). 
The role and time point of inflammation with regard to edema formation might tough not 
necessarily be the same, being aware of the substantial differences in pathogenesis of 
ALI/ARDS [37] and HAPE [22]. In conclusion, cells at the alveolar barrier do not seem to be 
involved in pro-inflammatory actions under prolonged hypoxic conditions. If the in vitro 
observed positive effect of dexamethasone of maintaining ENaC function in hypoxic 
conditions contributes to improved fluid reabsorption in vivo in situations such as HAPE 
remains to the subject of further investigations. 
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Figure legends 
 
Figure 1: Schematic drawing of an alveolus in state of early inflammation. Effector cell 
recruitement by inflammatory mediators from pulmonary epithelial and endothelial cells is 
illustrated (left side). Water transport through ion channels located on the alveolar epithelial 
cell apical surface and baso-lateral membrane (right side) is impaired. Sodium enters the cell 
via apical epithelial sodium channels (ENaC). On the basolateral interface, sodium is 
excreted via Na+/K+-ATPase, while potassium enters the cell. Reabsoption of sodium goes 
along with the reabsorption of Cl
-
, which generates an osmotic driving force for the 
transepithelial movement of water. Radioactive marker ions (
22
Na
+
 for Na
+
 and 
86
Rb for K
+
) 
were used to measure the ion channel turnover. CINC-1=cytokine-induced neutrophil 
chemoattractant-1, MCP-1=monocyte chemoattractant protein-1, IL-6=interleukin-6.  
 
Figure 2: Alveolar epithelial cells. Production of inflammatory mediators from alveolar 
epithelial cells type II (L2, AEC) under hypoxic and normoxic conditions, with or without 
dexamethasone pretreatment: Protein concentrations in supernatants (left) and mRNA 
expression levels (right). Hypoxia decreased CINC-1 and MCP-1 expression (p<0.001), but 
not IL-6 protein secretion (p=0.08). Addition of dexamethasone under hypoxic conditions 
attenuated CINC-1 and MCP-1 levels even more (p<0.001).  CINC-1=cytokine-induced 
neutrophil chemoattractant-1, MCP-1=monocyte chemoattractant protein-1, IL-
6=interleukin-6.  
 
Figure 3: Rat pulmonary artery endothelial cells.  Production of inflammatory mediators 
from rat pulmonary endothelial cells (RPAEC) under hypoxic and normoxic conditions, with 
or without dexamethasone pretreatment: Protein concentrations in supernatants (left) and 
mRNA expression levels (right). Hypoxia decreased CINC-1 (p<0.001), but not MCP-1 or IL-
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6 protein expression. Dexamethasone attenuated MCP-1 secretion under normoxic and 
hypoxic conditions (p<0.001). CINC-1=cytokine-induced neutrophil chemoattractant-1, 
MCP-1=monocyte chemoattractant protein-1, ICAM-1=intercellular adhesion molecule-1.  
 
Figure 4: Alveolar macrophages.  Production of inflammatory mediators from alveolar 
macrophages (MAC) under hypoxic and normoxic conditions, with or without dexamethasone 
pretreatment: both, hypoxic conditions and dexamethasone treatment decreased Monocyte 
Chemoattractant Protein-1 (MCP-1) protein concentration (p<0.001), as well as MCP-1 and 
Intercellular Adhesion Molecule-1 (ICAM-1) mRNA levels (p<0.05) in alveolar macrophages.  
Cytokine-induced neutrophil chemoattractant-1 and Interleukin-6 protein was not detectable 
in supernatants. 
 
Figure 5: Activation of hypoxic-inducible factor attenuates inflammatory mediator 
expression. Similar as in experiments using exposure to hypoxia (5% oxygen), inflammatory 
mediator secretion is attenuated (p<0.001) in alveolar epithelial cells (AEC) stimulated with 
1mM N-(Methoxyoxoacetyl)-glycine methyl ester (DMOG, an inhibitor of prolyl-4-
hydroxylase). CINC-1=cytokine-induced neutrophil chemoattractant-1, MCP-1=monocyte 
chemoattractant protein-1.  
 
Figure 6: Ion channel expression and function. Expression of apical epithelial sodium 
channel (αENaC) and basolateral Na+/K+-ATPase (mRNA-expression, left) with 
corresponding actual channel turnover measured by radioactive tracer ions (amiloride-
sensitive 
22
Na uptake for ENaC function, Ouabain-sensitive 
86
Rubidium uptake for Na+/K+-
ATPase function, right). Total 
22
Na flux was decreased after exposure to hypoxia (p<0.001). 
When preincubated with dexamethasone 
22
Na flux was partially maintained (p=0.001). In 
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contrast, no increased 
86
Rubidium uptake upon dexamethasone treatment was observed. 
Co=control, Hyp=hypoxia, Dex=dexamethasone 
 
Figure 7: Viability. Alveolar epithelial cells (AEC,) rat pulmonary artery endothelial cells 
(RPAEC), and alveolar macrophages (MAC) were pretreated with dexamethasone (or not) 
and exposed to 5% oxygen (or 21% as control) for 24 hours. MTT assays were performed: no 
influences of variations in viability on inflammatory mediator expression or ion fluxes were 
found.  
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Figures 
Figure 1: Schematic drawing of an alveolus in state of early inflammation. 
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Figure 2: Alveolar epithelial cells. 
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Figure 3: Rat pulmonary artery endothelial cells.   
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Figure 4: Alveolar macrophages.   
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Figure 5: Activation of hypoxic-inducible factor attenuates inflammatory mediator 
expression. 
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Figure 6: Ion channel expression and function. 
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Figure 7: Viability. 
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Figure S1: Intercellular adhesion molecule-1 (ICAM-1) expression in alveolar epithelial cells (AEC). AEC were 
pretreated with dexamethasone (or not) and exposed to 5% oxygen (or 21% as control) for 24 hours. Cell-based 
ELISA was performed (A) or mRNA determined (B).  
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Table S1: TaqMan primers and probes 
Gene Primer sequence Fragment size 
CINC-1 
forward: 5’ cac act cca aca gag cac ca 3’ 
reverse: 5’ tga cag cgc acg tca ttg 3’ 
probe #49 
120bp 
MCP-1 
forward: 5’ acg atc cac gtg gtg tct c 3’ 
reverse: 5’ gat cat ctt gcc agt gaa tga gt 3’ 
probe #62 
78bp 
IL-6 
forward: 5’ ccc ttc agg aac agc tat gaa 3’ 
reverse: 5’ aca aca tca gtc cca aga agg 3’ 
probe #20 
74bp 
ICAM-1 
forward: 5’ aac ctc agc ctc gct atg g 3’ 
reverse: 5’ act ttt gag ggg gac aca ga 3’ 
probe #62 
95bp 
αENaC 
forward: 5’ tgt gac tac cga aag cag agc 3’ 
reverse: 5’ agg ctt ccg aca ctt gga g 3’ 
probe #26 
102bp 
αNa+/K+-ATPase 
forward: 5’ act tgg gca ctg aca tgg tt 3’ 
reverse: 5’ cac aag ttt gtc cgt ttt gg 3’ 
probe #26 
104bp 
18S 
forward: 5’ gga gag gga gcc tga gaa ac 3’ 
reverse: 5’ tcg gga gtg ggt aat ttg c 3’ 
probe #74 
70bp 
 
CINC-1 = cytokine-induced neutrophil chemoattractant-1; MCP-1 = monocyte chemoattractant protein-1; IL-6 = 
interleukin-6; ICAM-1 = intercellular adhesion molecule-1; αENaC = alpha subunit epithelial sodium channel 
Page 60 of 67Clinical Experimental Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 4
Table S2: Linear regression on expression of inflammatory mediator protein expression in alveolar epithelial cells (AEC) 
 
CINC-1 = cytokine-induced neutrophil chemoattractant-1; MCP-1 = monocyte chemoattractant protein-1; IL-6 = interleukin-6; ICAM-1 = intercellular adhesion molecule-1; 
sign = significance; Hyp = hypoxia, Dex = dexamethasone 
 
 
Unstandardized 
Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients Sign. R2 N 
B Lower Bound 
Upper 
Bound Beta 
CINC-1 Hyp -38.950 -53.645 -24.255 -5.319 < .001 * 
.568 57.000 
Hyp+Dex -55.972 -69.697 -42.247 -8.183 < .001 * 
Dex -32.392 -46.663 -18.121 -4.555 < .001 * 
Viability (MTT) .007 -.308 .322 .045 .964 
MCP-1 Hyp -42.049 -57.819 -26.280 -.434 < .001 * 
.757 72 
Hyp+Dex -90.593 -104.611 -76.575 -1.023 < .001 * 
Dex -82.096 -96.135 -68.057 -.913 < .001 * 
Viability (MTT) .038 -.277 .352 .016 .811 
IL-6 Hyp -22.051 -46.827 2.724 -.249 .080 
.380 57.000 Hyp+Dex -61.781 -84.920 -38.641 -.762 < .001 * 
Dex -36.450 -60.510 -12.390 -.433 .004 * 
Viability (MTT) .152 -.379 .683 .066 .568 
ICAM-1 Hyp 4.368 -18.432 27.167 .068 .702 
.076 53 Hyp+Dex 7.766 -14.825 30.358 .120 .493 
Dex -11.404 -33.547 10.739 -.185 .306 
Viability (MTT) .039 -.454 .532 .023 .874 
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Table S3: Linear regression on expression of inflammatory mediator protein expression in rat pulmonary artery endothelial cells (RPAEC) 
 
CINC-1 = cytokine-induced neutrophil chemoattractant-1; MCP-1 = monocyte chemoattractant protein-1; IL-6 = interleukin-6; ICAM-1 = intercellular adhesion molecule-1; 
sign = significance; Hyp = hypoxia, Dex = dexamethasone 
 
 
Unstandardized 
Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients Sign. R2 N 
B Lower Bound 
Upper 
Bound Beta 
CINC-1 Hyp -35.456 -48.336 -22.576 -.730 < .001 * 
0.772 38 
Hyp+Dex -46.665 -57.129 -36.201 -.961 < .001 * 
Dex -10.612 -21.796 .572 -.233 .062 
Viability (MTT) -.036 -.468 .396 -.025 .866 
MCP-1 Hyp -5.529 -27.716 16.657 -.070 .619 
0.575 55 
Hyp+Dex -52.210 -68.992 -35.428 -.731 < .001 * 
Dex -47.483 -66.529 -28.437 -.678 < .001 * 
Viability (MTT) -.089 -.775 .598 -.040 .796 
IL-6 Hyp 
Values below detection limit of the ELISA Hyp+Dex 
Dex 
Viability (MTT) 
ICAM-1 Hyp 4.781 -8.300 17.863 .186 .463 
0.095 40 Hyp+Dex 3.268 -7.209 13.745 .136 .531 
Dex -.426 -11.838 10.987 -.018 .940 
Viability (MTT) -.095 -.524 .333 -.125 .654 
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Table S4: Linear regression on expression of inflammatory mediator protein expression in alveolar macrophages (MAC) 
 
CINC-1 = cytokine-induced neutrophil chemoattractant-1; MCP-1 = monocyte chemoattractant protein-1; IL-6 = interleukin-6; ICAM-1 = intercellular adhesion molecule-1; 
sign = significance; Hyp = hypoxia, Dex = dexamethasone 
 
 
Unstandardized 
Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients Sign. R2 N 
B Lower Bound 
Upper 
Bound Beta 
CINC-1 Hyp 
Values below detection limit of the ELISA Hyp+Dex 
Dex 
Viability (MTT) 
MCP-1 Hyp -31.537 -39.107 -23.968 -.357 < .001 * 
0.851 140 
Hyp+Dex -90.844 -98.354 -83.334 -1.027 < .001 * 
Dex -87.533 -95.857 -79.209 -.870 < .001 * 
Viability (MTT) -10.073 -24.929 4.782 -.046 .182 
IL-6 Hyp 
Values below detection limit of the ELISA Hyp+Dex 
Dex 
Viability (MTT) 
ICAM-1 Hyp 
Cell-based ELISA not applicable (adherence is a prerequisite) Hyp+Dex 
Dex 
Viability (MTT) 
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Table S5: Linear regression on expression of inflammatory mediator expression after stimulation with DMOG 
 
CINC-1 = cytokine-induced neutrophil chemoattractant-1; MCP-1 = monocyte chemoattractant protein-1; DMOG = N-(Methoxyoxoacetyl)-glycine methyl ester 
B = beta coefficient; sign = significance 
 
CINC-1 protein 
 
Independent variables 
Unstandardized 
Coefficients 95.0% Confidence Interval for B 
Standardized 
Coefficients Sign. 
B Lower Bound Upper Bound Beta 
DMOG -44.167 -51.313 -37.021 -.845 < .001 * 
DMOG + Dexamethasone -59.500 -66.646 -52.354 -1.138 < .001 * 
Dexamethasone -40.167 -47.313 -33.021 -.768 < .001 * 
 
R2: 0.934; N=24; dependent variable: CINC-1 protein 
 
MCP-1 protein 
 
Independent variables 
Unstandardized 
Coefficients 95.0% Confidence Interval for B 
Standardized 
Coefficients Sign. 
B Lower Bound Upper Bound Beta 
DMOG -1217.167 -1470.948 -963.385 -1.013 < .001 * 
DMOG + Dexamethasone -1092.167 -1345.948 -838.385 -.909 < .001 * 
Dexamethasone -998.000 -1251.781 -744.219 -.830 < .001 * 
      
R2: 0.863; N=24; dependent variable: MCP-1 protein 
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Table S6: Linear regression regarding influence of hypoxia and dexamethasone on 22sodium uptake 
 
Hyp = hypoxia, Dex = dexamethasone; sign = significance; dependent variable: 22 sodium uptake 
 
 
Unstandardized 
Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients Sign. R2 N 
B Lower Bound 
Upper 
Bound Beta 
Hyp -41.790 -60.044 -23.537 -.660 < .001 * 
0.415 58 
Hyp+Dex -29.838 -47.192 -12.483 -.487 .001 * 
Dex -22.517 -39.744 -5.289 -.368 .011 * 
Viability (MTT) -.077 -.409 .256 -.052 .645 
Amiloride-sensitivity -45.141 -62.290 -27.991 -.759 < .001 * 
 
 
Influences of dexamethasone / hypoxia on amiloride-insensitive 22 sodium uptake 
 
 
Unstandardized 
Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients Sign. R2 N 
B Lower Bound 
Upper 
Bound Beta 
Hyp + Amiloride -9.395 -27.552 8.762 -.349 .267 
0.645 15 
Hyp+Dex +  Amiloride -2.181 -17.614 13.251 -.095 .753 
Dex +  Amiloride 13.006 -4.841 30.854 .483 .131 
Viability (MTT) -.063 -.448 .322 -.105 .714 
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Table S7: Linear regression regarding influence of hypoxia and dexamethasone on 86rubidium uptake 
 
Hyp = hypoxia, Dex = dexamethasone; sign = significance; dependent variable: 86 rubidium uptake 
 
 
Unstandardized 
Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients Sign. R2 N 
B Lower Bound 
Upper 
Bound Beta 
Hyp .446 -6.078 6.971 .006 .892 
0.900 95 
Hyp+Dex -5.684 -12.026 .658 -.076 .078 
Dex -14.415 -20.858 -7.972 -.188 < .001 * 
Viability (MTT) .009 -.107 .124 .005 .884 
Ouabain-sensitivity -67.760 -73.771 -61.749 -1.004 < .001 * 
 
 
Influences of dexamethasone / hypoxia on ouabain-insensitive 86 rubidium uptake 
 
 
Unstandardized 
Coefficients 
95.0% Confidence 
Interval for B 
Standardized 
Coefficients Sign. R2 N 
B Lower Bound 
Upper 
Bound Beta 
Hyp + Ouabain -6.508 -15.335 2.319 -.360 .139 
0.582 24 
Hyp+Dex +  Ouabain -10.756 -19.395 -2.117 -.595 .017 
Dex +  Ouabain -.883 -9.861 8.096 -.049 .839 
Viability (MTT) .147 -.059 .352 .311 .151 
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Table S8: Correlation analysis on mRNA expression and measured inflammatory mediator protein levels in 
alveolar epithelial cells (AEC). 
 
 
Correlation 
Coefficient Sig. (2-tailed) N 
CINC-1 .448 5.307E-04 ** 56 
MCP-1 .564 4.0145E-06 ** 58 
IL-6 .280 3.654E-02 * 56 
ICAM-1 -0.134 0.328 55 
 
* Correlation is significant at the 0.05 level (2-tailed). 
 
** Correlation is significant at the 0.01 level (2-tailed). 
 
CINC-1 = cytokine-induced neutrophil chemoattractant-1; MCP-1 = monocyte chemoattractant protein-1; IL-6 = 
interleukin-6; ICAM-1 = intercellular adhesion molecule-1; sig = significance 
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